BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25719943)

  • 1. Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
    Mu Q; Wang L; Yu F; Gao H; Lei T; Li P; Liu P; Zheng X; Hu X; Chen Y; Jiang Z; Sayari AJ; Shen J; Huang H
    Cancer Biol Ther; 2015; 16(4):623-33. PubMed ID: 25719943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
    Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
    Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells.
    Lin YC; Lin JC; Hung CM; Chen Y; Liu LC; Chang TC; Kao JY; Ho CT; Way TD
    J Agric Food Chem; 2014 Jun; 62(22):5061-71. PubMed ID: 24828835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulated circular RNA hsa_circ_0067934 contributes to glioblastoma progression through activating PI3K-AKT pathway.
    Xin J; Zhang XY; Sun DK; Tian LQ; Xu P
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3447-3454. PubMed ID: 31081099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
    Chen CM; Syu JP; Way TD; Huang LJ; Kuo SC; Lin CT; Lin CL
    Int J Mol Med; 2015 Nov; 36(5):1244-52. PubMed ID: 26329365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
    Huang BS; Luo QZ; Han Y; Huang D; Tang QP; Wu LX
    J Cell Biochem; 2017 Oct; 118(10):3452-3461. PubMed ID: 28332226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
    Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
    BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
    Zhong C; Chen Y; Tao B; Peng L; Peng T; Yang X; Xia X; Chen L
    BMC Cancer; 2018 Jul; 18(1):722. PubMed ID: 29980193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
    Tang H; Zhao J; Zhang L; Zhao J; Zhuang Y; Liang P
    Cell Mol Neurobiol; 2016 Oct; 36(7):1067-76. PubMed ID: 26643178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1.
    Dai N; Ji F; Wright J; Minichiello L; Sadreyev R; Avruch J
    Elife; 2017 Jul; 6():. PubMed ID: 28753127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
    Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
    Matias D; Balça-Silva J; Dubois LG; Pontes B; Ferrer VP; Rosário L; do Carmo A; Echevarria-Lima J; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
    Cell Oncol (Dordr); 2017 Jun; 40(3):247-261. PubMed ID: 28401486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
    Koch K; Hartmann R; Schröter F; Suwala AK; Maciaczyk D; Krüger AC; Willbold D; Kahlert UD; Maciaczyk J
    Oncotarget; 2016 Nov; 7(45):73414-73431. PubMed ID: 27705917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.